COLUMBIA, Md., Nov. 13, 2017 (GLOBE NEWSWIRE) — WellDoc®, a leading digital health company, announced today that IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar®, WellDoc’s FDA-cleared, proven digital therapeutic for people living with type 2 diabetes, the “top app” in the category of clinical diabetes treatment. The related report entitled, “The Growing Value of Digital Health: Evidence and Impact on Human Health and the Healthcare System,” featured the top-rated apps for patients to manage conditions including cancer, diabetes, hypertension and asthma.
“It’s an honor to have IQVIA name BlueStar as the top app in the category of clinical diabetes treatment,” said WellDoc’s CEO Kevin McRaith. “IQVIA, who we’ve known for years as Quintiles/IMS, is a leading global provider of information that focuses on using data and science to help healthcare clients find better solutions for their patients.”
IQVIA rated the apps via scores calculated using a proprietary system that takes into account many factors including: approvals by healthcare providers, patient ratings, endorsements from regulators and clinicians, and peer-reviewed articles.
Click here to read the full press release.